| 摘要 |
PURPOSE: To obtain the subject agent containing, as active ingredients, trans- retionic acid and a vitamin D3 analogue, and exhibiting synergistic anti-leukemic effect on leukemia, esp. myelogenous leukemic cells. CONSTITUTION: This therapeutic agent contains, as active ingredients, (A) trans- retinoic acid and (B) a vitamin D3 analogue (pref. 1α, 25-dihydroxy-16-ene- cholecalciferol). The daily doses of the ingredients A and B are pref. 7 mg and 0.007 mg, respectively, and, in general, the dose of the ingredient A is 100-1,000 times that of the ingredient B.
|
